Sat, Jul 26, 2014, 1:29 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Corning Inc. Message Board

lws2000 196 posts  |  Last Activity: 16 hours ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • NOTE: These excerpts from a previous discussion tell the full story. Basically Imetelstat works, while all other treatments fail (remissions, cures, cost, etc.) There is nothing else.
    -----------------------------------------------------------------------------------------
    #######FROM prescient2001 (negative argument)

    Cost per treatment hasn't been discussed recently. It sounds like Irish's husband currently is benefited most by infusions every 6 weeks (approx 9x/yr.). To the degree it's quickly covered by insurance, great, but, if Jakafi is significantly less expensive, it might remain the treatment of choice for older patients. A drug combo with Jakafi may not be a money saver if the same amount of Imetalstat is required to successfully treat the cancer.

    . .
    ******** FROM irishtrader52 • 4 hours ago (positive facts)

    Jakafi is not an option due to minimal efficacy/severe side effects/lack of durability and not less expensive as Jakafi patients get sicker and sicker costing much much more in medical costs than patients in remission. Our insurance company has easily saved huge costs the past 18 months thanks to Imetelstat! Transfusions alone - and Jakafi can accelerate the need to transfuse - would have cost more than Imetelstat not to mention the hospitalizations and hospice care needed as his organs slowly shut down one organ at a time and he bled out slowly. MF is a slow agonizing way to die - a "wasting" disease.

  • More on the Great Mayo-FDA-Geron Mystery; Explosion Coming

    As a matter of policy, when Mayo takes on an "iffy", unproven drug like Imetelstat, they know very few will succeed, and most will strike out. Even with drugs (especially cancer drugs) that seem to help, most ultimately fail due to safety problems (the drug is worse than the disease). In this sense, Imetelstat is at least a triple, and perhaps a home run (safe & effective). Mayo knows that, and in all cases, carefully protects its researchers and their limited successes, by written agreements. Geron cannot operate independently with Imetelstat. Consider the Mayo-Geron-FDA decisions as a single package, with Mayo in control. This actually strengthens Geron, which does not have Mayo's stature or the FDA's ear. Much of the market believes that Geron is a "screw-up" company, and cannot succeed. IMO, the science and good medicine at Mayo, trumps the markets opinions eventually (before ASH I believe).

    PREVIOUS "Here is the Mystery. The science & medical community (led by Mayo Clinic, #1 in the USA) say that Imetelstat is safe, effective and a "miracle drug". The markets & big pharma should be beating down the doors, yet the stock is in the $2's. $10 is coming before ASH, since Mayo tells the truth, and there is no fraud. There may be rigged markets, but that is beyond my perception and understanding."

    Mayo will eventually dominate and raise all boats (including Geron's). There are rigged markets no doubt, that, somehow, are controlling the price of Geron's stock (short term). Mayo must have complete control of Geron, since all moves concerning Imetelstat have to be approved by Mayo, and Geron is unstable. Mayo is setting up a world wide network of clinics, countries and pipelines, with the FDA looking over their shoulder. The explosion is coming.

  • lws2000 lws2000 Jul 24, 2014 3:05 PM Flag

    I can tell you for a fact, that Mayo Clinic would not have touched Imetelstat, unless they could control its path forward, if successful. Geron, of course, benefits from the MF results, but that is not apparent from the stock price (~$2.50).

  • PREVIOUS "Here is the Mystery. The science & medical community (led by Mayo Clinic, #1 in the USA) say that Imetelstat is safe, effective and a "miracle drug". The markets & big pharma should be beating down the doors, yet the stock is in the $2's. $10 is coming before ASH, since Mayo tells the truth, and there is no fraud. There may be rigged markets, but that is beyond my perception and understanding."

    Mayo will eventually dominate and raise all boats (including Geron's). There are rigged markets no doubt, that, somehow, are controlling the price of Geron's stock (short term). Mayo must have complete control of Geron, since all moves concerning Imetelstat have to be approved by Mayo, and Geron is unstable. Mayo is setting up a world wide network of clinics, countries and pipelines, with the FDA looking over their shoulder. The explosion is coming.

  • Reply to

    timberrrrrr ! the terrible twos !

    by circone Jul 24, 2014 10:30 AM
    lws2000 lws2000 Jul 24, 2014 10:40 AM Flag

    That is the Mystery. The science & medical community (led by Mayo Clinic, #1 in the USA) say that Imetelstat is safe, effective and a "miracle drug". The markets & big pharma should be beating down the doors, yet the stock is in the $2's. $10 is coming, since Mayo tells the truth, and there is no fraud. There may be rigged markets, but that is beyond my perception.

  • PREVIOUS: "Mayo has published the "good news" about Imetelstat, but the market still has no clue. This is a mystery. Seeking Alpha notes, that this stock is about to explode. There can be no other outcome. $10 sometime between next week and the next ASH conference. I don't know exactly when, but it is coming."

    The "Mystery" is that everyone (in science & medical community that cares) knows that Imetelstat is a "miracle drug" and Mayo is now shouting it from the roof tops. So why doesn't the general market get it? The answer seems to be in the Mayo-FDA-Geron arrangements and contracts, since no one seems to believe that the Mayo trials and results are fraudulent. Mayo is in control, and Geron's hands are tied (by Mayo & the FDA). In addition, we now have the Yale input (p21, p53, telomeres, etc.). Great things are coming, but, so far, the market does not get it.

  • Mayo has published the "good news" about Imetelstat, but the market still has no clue. This is a mystery. Seeking Alpha notes, that this stock is about to explode. There can be no other outcome. $10 sometime between next week and the next ASH conference. I don't know exactly when, but it is coming.

  • How can we get this information to Yahoo (about bashers and good information)?

    PREVIOUS: Miracle Drug, P21, Mystery, Mayo

    With this new format, it will be difficult to have a continuing conversation, that doesn't get lost in the bashing jimberish.

    PREVIOUS: "All looks good. Researchers (Yale) uncover new cancer cell vulnerability (Fri, 07/18/2014)--telomeres & p21. Geron has a working, "miracle drug" and a "great pipeline". It is a "Mystery" why this stock isn't soaring with so much proven and so much potential."

    Mayo is the defining entity here. They have the MF patients and the trials that have been successful, and have the complete trust of the FDA. If all is kosher, this should be a $10 stock right now. The Mayo-Geron contract is the major mystery, with Mayo in control, and Geron doing what they are told to do (under the contract). Big pharma has to be interested."

  • With this new format, it will be difficult to have a continuing conversation, that doesn't get lost in the bashing jimberish.

    PREVIOUS: "All looks good. Researchers (Yale) uncover new cancer cell vulnerability (Fri, 07/18/2014)--telomeres & p21. Geron has a working, "miracle drug" and a "great pipeline". It is a "Mystery" why this stock isn't soaring with so much proven and so much potential."

    Mayo is the defining entity here. They have the MF patients and the trials that have been successful, and have the complete trust of the FDA. If all is kosher, this should be a $10 stock right now. The Mayo-Geron contract is the major mystery, with Mayo in control, and Geron doing what they are told to do (under the contract). Big pharma has to be interested.

  • I think (as others have put forward) that the "Mystery" is in the arrangements that Mayo has with Geron. Imelelstat had known potential from the animal studies, but so many drugs that work for animals fail the human test. Imetelstat appears to be the exception. To conduct the human trials, I believe that Mayo required very strict control. Imetelstat will move along on Mayo's schedule, with Mayo's plan, IMO. Geron is following the Mayo-Geron contract, which investors have not seen.

    The FDA would rather deal with Mayo, who has all of the MF trials and patients. All looks good, but Mayo & the FDA are being very cautious. That is time consuming, but Mayo & the FDA must have their reasons. Geron will eventually benefit, but (when?) is everyone's question.

  • All looks good. Researchers (Yale) uncover new cancer cell vulnerability (Fri, 07/18/2014)--telomeres & p21. Geron has a working, "miracle drug" and a "great pipeline". It is a "Mystery" why this stock isn't soaring with so much proven and so much potential.

  • Xilinx sell-off brings 'great' entry point, says FBR Capital
    FBR Capital says the post-earnings sell-off in shares of Xilinx provides a "great" entry point into the name. FBR lowered its price target for Xilinx to $62 from $65 and keeps an Outperform rating on the stock. Shares were downgraded this morning at three firms.

  • lws2000 lws2000 Jul 22, 2014 10:40 AM Flag

    Mayo knows what it is doing. The potential for telomere research and breakthroughs is almost infinite.

  • Imetelstat and Yale: New Combination Opportunities for Imetelstat

    Interesting:

    Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

    Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The telomerase enzyme is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Dept. of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing cancer cells.

    Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

    Source: Yale Univ.

  • Reply to

    GERON MGMT MOVES TOO SLOWLY...

    by micaiah2004 Jul 21, 2014 7:07 PM
    lws2000 lws2000 Jul 21, 2014 9:14 PM Flag

    This is Mayo's game. Mayo took on the Imetelstat project with a certain level of exclusivity, since the outcome was highly speculative. Perhaps 1 in 20 of these drugs work out at all. The level of success here is rare. Mayo will dictate where and when this drug is used, at least for now. That is why Geron is so passive.

  • lws2000 lws2000 Jul 21, 2014 5:44 PM Flag

    Interesting:

    Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

    Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The telomerase enzyme is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Dept. of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing cancer cells.

    Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

    Source: Yale Univ.

  • Reply to

    No Hidden Bad News About Imetelstat

    by lws2000 Jul 17, 2014 10:19 AM
    lws2000 lws2000 Jul 18, 2014 7:30 PM Flag

    I said, "Nothing is further from the truth, as Mayo (USA #1) continues full support". I have full confidence in Mayo (their data, patients and trials). As long as Mayo is upbeat, I will continue my long investment in Geron. Either there is something that we don't know that is devastating (don't think so), or as you say Imetelstat is likely a medical marvel. Actually, I am investing in Mayo Clinic's reputation. Geron is a bit mysterious, with some questionable history. Mayo, IMO, will keep Geron reasonably honest.

  • Reply to

    No Hidden Bad News About Imetelstat

    by lws2000 Jul 17, 2014 10:19 AM
    lws2000 lws2000 Jul 17, 2014 11:30 AM Flag

    Remissions & Cures with telomere control

  • The way Geron stock is acting one would think that announcements of Imelestat's failures are imminent. Nothing is further from the truth, as Mayo (USA #1) continues full support.

GLW
22.02-0.07(-0.32%)Jul 25 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.